AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
- ByBenzinga-
AstraZeneca Plc (NASDAQ: AZN) reported topline data from the DESTINY-Breast02 phase 3 trial of Enhertu (trastuzumab deruxtecan).The trial evaluated Enhertu versus...